APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurometabolic Disorders

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurometabolic Disorders Market Outlook and Growth Opportunities 2026

Report ID 174016590419 December 2025206 pages

Choose your research edition.

Industry ResearchNeurometabolic Disorders Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurometabolic Disorders Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurometabolic Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurometabolic Disorders Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurometabolic Disorders Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Neurometabolic Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurometabolic Disorders market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurometabolic Disorders market include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurometabolic Disorders market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurometabolic Disorders and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurometabolic Disorders revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurometabolic Disorders market.

Neurometabolic Disorders Segment by Company

Amicus

Amicus Therapeutics

Biomarin

Biosidus

Dong-A Socio Group

ExSAR Corporation

Genzyme

Greencross

Greenovation Biotech

ISU Abxis

JCR Pharmaceuticals

Lixte Biotechnology

Neuraltus Pharmaceuticals

Pharming Group

Protalix

Protalix BioTherapeutics

Shire

UAB Proforma

Neurometabolic Disorders Segment by Type

Pompe Disease

Mucopolysaccharidosis VI

Gaucher’s Disease

Fabry Disease

Other

Neurometabolic Disorders Segment by Application

Oral

Parenteral

Neurometabolic Disorders Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neurometabolic Disorders status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurometabolic Disorders key companies, revenue, market share, and recent developments.

3. To split the Neurometabolic Disorders breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurometabolic Disorders market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurometabolic Disorders significant trends, drivers, influence factors in global and regions.

6. To analyze Neurometabolic Disorders competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurometabolic Disorders industry.

Chapter 3: Detailed analysis of Neurometabolic Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurometabolic Disorders in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurometabolic Disorders in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurometabolic Disorders Industry Trends Table 2. Neurometabolic Disorders Industry Drivers Table 3. Neurometabolic Disorders Industry Opportunities and Challenges Table 4. Neurometabolic Disorders Industry Restraints Table 5. Global Neurometabolic Disorders Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurometabolic Disorders Revenue Share by Company (2021-2026) Table 7. Global Neurometabolic Disorders Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurometabolic Disorders Key Company Manufacturing Base & Headquarters Table 9. Global Neurometabolic Disorders Company, Product Type & Application Table 10. Global Neurometabolic Disorders Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurometabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pompe Disease Table 15. Significant Companies of Mucopolysaccharidosis VI Table 16. Significant Companies of Gaucher’s Disease Table 17. Significant Companies of Fabry Disease Table 18. Significant Companies of Other Table 19. Global Neurometabolic Disorders Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Neurometabolic Disorders Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Neurometabolic Disorders Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Neurometabolic Disorders Sales Value Share by Type (2021-2026) Table 23. Global Neurometabolic Disorders Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Oral Table 25. Significant Companies of Parenteral Table 26. Global Neurometabolic Disorders Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neurometabolic Disorders Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Neurometabolic Disorders Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Neurometabolic Disorders Sales Value Share by Application (2021-2026) Table 30. Global Neurometabolic Disorders Sales Value Share by Application (2027-2032) Table 31. Global Neurometabolic Disorders Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neurometabolic Disorders Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Neurometabolic Disorders Sales Value Share by Region (2021-2026) Table 34. Global Neurometabolic Disorders Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Neurometabolic Disorders Sales Value Share by Region (2027-2032) Table 36. Global Neurometabolic Disorders Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neurometabolic Disorders Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Neurometabolic Disorders Sales Value Market Share by Country (2021-2026) Table 39. Global Neurometabolic Disorders Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Neurometabolic Disorders Sales Value Market Share by Country (2027-2032) Table 41. Amicus Company Information Table 42. Amicus Business Overview Table 43. Amicus Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Amicus Neurometabolic Disorders Product Portfolio Table 45. Amicus Recent Development Table 46. Amicus Therapeutics Company Information Table 47. Amicus Therapeutics Business Overview Table 48. Amicus Therapeutics Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Amicus Therapeutics Neurometabolic Disorders Product Portfolio Table 50. Amicus Therapeutics Recent Development Table 51. Biomarin Company Information Table 52. Biomarin Business Overview Table 53. Biomarin Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Biomarin Neurometabolic Disorders Product Portfolio Table 55. Biomarin Recent Development Table 56. Biosidus Company Information Table 57. Biosidus Business Overview Table 58. Biosidus Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Biosidus Neurometabolic Disorders Product Portfolio Table 60. Biosidus Recent Development Table 61. Dong-A Socio Group Company Information Table 62. Dong-A Socio Group Business Overview Table 63. Dong-A Socio Group Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Dong-A Socio Group Neurometabolic Disorders Product Portfolio Table 65. Dong-A Socio Group Recent Development Table 66. ExSAR Corporation Company Information Table 67. ExSAR Corporation Business Overview Table 68. ExSAR Corporation Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ExSAR Corporation Neurometabolic Disorders Product Portfolio Table 70. ExSAR Corporation Recent Development Table 71. Genzyme Company Information Table 72. Genzyme Business Overview Table 73. Genzyme Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Genzyme Neurometabolic Disorders Product Portfolio Table 75. Genzyme Recent Development Table 76. Greencross Company Information Table 77. Greencross Business Overview Table 78. Greencross Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Greencross Neurometabolic Disorders Product Portfolio Table 80. Greencross Recent Development Table 81. Greenovation Biotech Company Information Table 82. Greenovation Biotech Business Overview Table 83. Greenovation Biotech Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Greenovation Biotech Neurometabolic Disorders Product Portfolio Table 85. Greenovation Biotech Recent Development Table 86. ISU Abxis Company Information Table 87. ISU Abxis Business Overview Table 88. ISU Abxis Neurometabolic Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. ISU Abxis Neurometabolic Disorders Product Portfolio Table 90. ISU Abxis Recent Development Table 91. JCR Pharmaceuticals Company Information Table 92. JCR Pharmaceuticals Business Overview Table 93. JCR Pharmaceuticals Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 95. JCR Pharmaceuticals Recent Development Table 96. Lixte Biotechnology Company Information Table 97. Lixte Biotechnology Business Overview Table 98. Lixte Biotechnology Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lixte Biotechnology Neurometabolic Disorders Product Portfolio Table 100. Lixte Biotechnology Recent Development Table 101. Neuraltus Pharmaceuticals Company Information Table 102. Neuraltus Pharmaceuticals Business Overview Table 103. Neuraltus Pharmaceuticals Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 105. Neuraltus Pharmaceuticals Recent Development Table 106. Pharming Group Company Information Table 107. Pharming Group Business Overview Table 108. Pharming Group Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pharming Group Neurometabolic Disorders Product Portfolio Table 110. Pharming Group Recent Development Table 111. Protalix Company Information Table 112. Protalix Business Overview Table 113. Protalix Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Protalix Neurometabolic Disorders Product Portfolio Table 115. Protalix Recent Development Table 116. Protalix BioTherapeutics Company Information Table 117. Protalix BioTherapeutics Business Overview Table 118. Protalix BioTherapeutics Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio Table 120. Protalix BioTherapeutics Recent Development Table 121. Shire Company Information Table 122. Shire Business Overview Table 123. Shire Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Shire Neurometabolic Disorders Product Portfolio Table 125. Shire Recent Development Table 126. UAB Proforma Company Information Table 127. UAB Proforma Business Overview Table 128. UAB Proforma Neurometabolic Disorders Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. UAB Proforma Neurometabolic Disorders Product Portfolio Table 130. UAB Proforma Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Neurometabolic Disorders Product Image Figure 2. Global Neurometabolic Disorders Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurometabolic Disorders Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurometabolic Disorders Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pompe Disease Image Figure 8. Mucopolysaccharidosis VI Image Figure 9. Gaucher’s Disease Image Figure 10. Fabry Disease Image Figure 11. Other Image Figure 12. Global Neurometabolic Disorders Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Neurometabolic Disorders Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Neurometabolic Disorders Sales Value Share by Type (2021-2032) Figure 15. Oral Image Figure 16. Parenteral Image Figure 17. Global Neurometabolic Disorders Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neurometabolic Disorders Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neurometabolic Disorders Sales Value Share by Application (2021-2032) Figure 20. Global Neurometabolic Disorders Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Neurometabolic Disorders Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Neurometabolic Disorders Sales Value (2021-2032) & (US$ Million) Figure 23. North America Neurometabolic Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Neurometabolic Disorders Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Neurometabolic Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Neurometabolic Disorders Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Neurometabolic Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Neurometabolic Disorders Sales Value (2021-2032) & (US$ Million) Figure 29. South America Neurometabolic Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Neurometabolic Disorders Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Neurometabolic Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Neurometabolic Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Pompe Disease
  • Mucopolysaccharidosis VI
  • Gaucher’s Disease
  • Fabry Disease
  • Other
Applications
  • Oral
  • Parenteral
Companies covered
  • Amicus
  • Amicus Therapeutics
  • Biomarin
  • Biosidus
  • Dong-A Socio Group
  • ExSAR Corporation
  • Genzyme
  • Greencross
  • Greenovation Biotech
  • ISU Abxis
  • JCR Pharmaceuticals
  • Lixte Biotechnology
  • Neuraltus Pharmaceuticals
  • Pharming Group
  • Protalix
  • Protalix BioTherapeutics
  • Shire
  • UAB Proforma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurometabolic Disorders Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurometabolic Disorders Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurometabolic Disorders Market Dynamics
  1. 2.1 Neurometabolic Disorders Industry Trends
  2. 2.2 Neurometabolic Disorders Industry Drivers
  3. 2.3 Neurometabolic Disorders Industry Opportunities and Challenges
  4. 2.4 Neurometabolic Disorders Industry Restraints
3 Neurometabolic Disorders Market by Company
  1. 3.1 Global Neurometabolic Disorders Company Revenue Ranking in 2025
  2. 3.2 Global Neurometabolic Disorders Revenue by Company (2021-2026)
  3. 3.3 Global Neurometabolic Disorders Company Ranking (2024-2026)
  4. 3.4 Global Neurometabolic Disorders Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurometabolic Disorders Company Product Type and Application
  6. 3.6 Global Neurometabolic Disorders Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurometabolic Disorders Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurometabolic Disorders Market by Type
  1. 4.1 Neurometabolic Disorders Type Introduction
  2. 4.1.1 Pompe Disease
  3. 4.1.2 Mucopolysaccharidosis VI
  4. 4.1.3 Gaucher’s Disease
  5. 4.1.4 Fabry Disease
  6. 4.1.5 Other
  7. 4.2 Global Neurometabolic Disorders Sales Value by Type
  8. 4.2.1 Global Neurometabolic Disorders Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neurometabolic Disorders Sales Value by Type (2021-2032)
  10. 4.2.3 Global Neurometabolic Disorders Sales Value Share by Type (2021-2032)
5 Neurometabolic Disorders Market by Application
  1. 5.1 Neurometabolic Disorders Application Introduction
  2. 5.1.1 Oral
  3. 5.1.2 Parenteral
  4. 5.2 Global Neurometabolic Disorders Sales Value by Application
  5. 5.2.1 Global Neurometabolic Disorders Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Neurometabolic Disorders Sales Value by Application (2021-2032)
  7. 5.2.3 Global Neurometabolic Disorders Sales Value Share by Application (2021-2032)
6 Neurometabolic Disorders Regional Value Analysis
  1. 6.1 Global Neurometabolic Disorders Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurometabolic Disorders Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurometabolic Disorders Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurometabolic Disorders Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurometabolic Disorders Sales Value (2021-2032)
  7. 6.3.2 North America Neurometabolic Disorders Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurometabolic Disorders Sales Value (2021-2032)
  10. 6.4.2 Europe Neurometabolic Disorders Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurometabolic Disorders Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurometabolic Disorders Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurometabolic Disorders Sales Value (2021-2032)
  16. 6.6.2 South America Neurometabolic Disorders Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurometabolic Disorders Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurometabolic Disorders Sales Value Share by Country, 2025 VS 2032
7 Neurometabolic Disorders Country-level Value Analysis
  1. 7.1 Global Neurometabolic Disorders Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurometabolic Disorders Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurometabolic Disorders Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurometabolic Disorders Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurometabolic Disorders Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurometabolic Disorders Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurometabolic Disorders Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amicus
  2. 8.1.1 Amicus Company Information
  3. 8.1.2 Amicus Business Overview
  4. 8.1.3 Amicus Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amicus Neurometabolic Disorders Product Portfolio
  6. 8.1.5 Amicus Recent Developments
  7. 8.2 Amicus Therapeutics
  8. 8.2.1 Amicus Therapeutics Company Information
  9. 8.2.2 Amicus Therapeutics Business Overview
  10. 8.2.3 Amicus Therapeutics Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio
  12. 8.2.5 Amicus Therapeutics Recent Developments
  13. 8.3 Biomarin
  14. 8.3.1 Biomarin Company Information
  15. 8.3.2 Biomarin Business Overview
  16. 8.3.3 Biomarin Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biomarin Neurometabolic Disorders Product Portfolio
  18. 8.3.5 Biomarin Recent Developments
  19. 8.4 Biosidus
  20. 8.4.1 Biosidus Company Information
  21. 8.4.2 Biosidus Business Overview
  22. 8.4.3 Biosidus Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biosidus Neurometabolic Disorders Product Portfolio
  24. 8.4.5 Biosidus Recent Developments
  25. 8.5 Dong-A Socio Group
  26. 8.5.1 Dong-A Socio Group Company Information
  27. 8.5.2 Dong-A Socio Group Business Overview
  28. 8.5.3 Dong-A Socio Group Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio
  30. 8.5.5 Dong-A Socio Group Recent Developments
  31. 8.6 ExSAR Corporation
  32. 8.6.1 ExSAR Corporation Company Information
  33. 8.6.2 ExSAR Corporation Business Overview
  34. 8.6.3 ExSAR Corporation Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio
  36. 8.6.5 ExSAR Corporation Recent Developments
  37. 8.7 Genzyme
  38. 8.7.1 Genzyme Company Information
  39. 8.7.2 Genzyme Business Overview
  40. 8.7.3 Genzyme Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Neurometabolic Disorders Product Portfolio
  42. 8.7.5 Genzyme Recent Developments
  43. 8.8 Greencross
  44. 8.8.1 Greencross Company Information
  45. 8.8.2 Greencross Business Overview
  46. 8.8.3 Greencross Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Greencross Neurometabolic Disorders Product Portfolio
  48. 8.8.5 Greencross Recent Developments
  49. 8.9 Greenovation Biotech
  50. 8.9.1 Greenovation Biotech Company Information
  51. 8.9.2 Greenovation Biotech Business Overview
  52. 8.9.3 Greenovation Biotech Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio
  54. 8.9.5 Greenovation Biotech Recent Developments
  55. 8.10 ISU Abxis
  56. 8.10.1 ISU Abxis Company Information
  57. 8.10.2 ISU Abxis Business Overview
  58. 8.10.3 ISU Abxis Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ISU Abxis Neurometabolic Disorders Product Portfolio
  60. 8.10.5 ISU Abxis Recent Developments
  61. 8.11 JCR Pharmaceuticals
  62. 8.11.1 JCR Pharmaceuticals Company Information
  63. 8.11.2 JCR Pharmaceuticals Business Overview
  64. 8.11.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  65. 8.11.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
  66. 8.11.5 JCR Pharmaceuticals Recent Developments
  67. 8.12 Lixte Biotechnology
  68. 8.12.1 Lixte Biotechnology Company Information
  69. 8.12.2 Lixte Biotechnology Business Overview
  70. 8.12.3 Lixte Biotechnology Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lixte Biotechnology Neurometabolic Disorders Product Portfolio
  72. 8.12.5 Lixte Biotechnology Recent Developments
  73. 8.13 Neuraltus Pharmaceuticals
  74. 8.13.1 Neuraltus Pharmaceuticals Company Information
  75. 8.13.2 Neuraltus Pharmaceuticals Business Overview
  76. 8.13.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
  78. 8.13.5 Neuraltus Pharmaceuticals Recent Developments
  79. 8.14 Pharming Group
  80. 8.14.1 Pharming Group Company Information
  81. 8.14.2 Pharming Group Business Overview
  82. 8.14.3 Pharming Group Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pharming Group Neurometabolic Disorders Product Portfolio
  84. 8.14.5 Pharming Group Recent Developments
  85. 8.15 Protalix
  86. 8.15.1 Protalix Company Information
  87. 8.15.2 Protalix Business Overview
  88. 8.15.3 Protalix Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Protalix Neurometabolic Disorders Product Portfolio
  90. 8.15.5 Protalix Recent Developments
  91. 8.16 Protalix BioTherapeutics
  92. 8.16.1 Protalix BioTherapeutics Company Information
  93. 8.16.2 Protalix BioTherapeutics Business Overview
  94. 8.16.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
  96. 8.16.5 Protalix BioTherapeutics Recent Developments
  97. 8.17 Shire
  98. 8.17.1 Shire Company Information
  99. 8.17.2 Shire Business Overview
  100. 8.17.3 Shire Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Shire Neurometabolic Disorders Product Portfolio
  102. 8.17.5 Shire Recent Developments
  103. 8.18 UAB Proforma
  104. 8.18.1 UAB Proforma Company Information
  105. 8.18.2 UAB Proforma Business Overview
  106. 8.18.3 UAB Proforma Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  107. 8.18.4 UAB Proforma Neurometabolic Disorders Product Portfolio
  108. 8.18.5 UAB Proforma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst